Jade Biosciences, Inc. Payments to Acquire Investments
Jade Biosciences, Inc. (JBIO) reported Payments to Acquire Investments of $216.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-10
- Jade Biosciences, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $142.32M.
- Jade Biosciences, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $73.90M.
- Jade Biosciences, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $112.60M.
- Jade Biosciences, Inc. payments to acquire investments for fiscal 2025 was $261.19M.
- Jade Biosciences, Inc. payments to acquire investments for fiscal 2021 was $113.25M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $216.22M 10-Q · filed 2026-08-10 | $328.82M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2026-03-31 | $73.90M 10-Q · filed 2026-05-07 | $186.50M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2025-12-31 | $112.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $261.19M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | $148.59M 10-Q · filed 2025-11-14 | |||
| 2021-12-31 | $113.25M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |